Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83

1.

CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.

Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, O'Hagan K, Ou J, Muller-Tidow C, Wolfe SA, Zhu LJ, Dekker J, Bushweller JH, Castilla LH.

Cell. 2018 Aug 23;174(5):1325. doi: 10.1016/j.cell.2018.08.014. No abstract available.

PMID:
30142347
2.

CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.

Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, O'Hagan K, Ou J, Muller-Tidow C, Wolfe SA, Zhu LJ, Dekker J, Bushweller JH, Castilla LH.

Cell. 2018 Jun 28;174(1):172-186.e21. doi: 10.1016/j.cell.2018.05.048. Erratum in: Cell. 2018 Aug 23;174(5):1325.

PMID:
29958106
3.

Small molecule inhibition of the CBFβ/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.

Carlton AL, Illendula A, Gao Y, Llaneza DC, Boulton A, Shah A, Rajewski RA, Landen CN, Wotton D, Bushweller JH.

Gynecol Oncol. 2018 May;149(2):350-360. doi: 10.1016/j.ygyno.2018.03.005. Epub 2018 Mar 16.

PMID:
29551565
4.

Solution structure and elevator mechanism of the membrane electron transporter CcdA.

Zhou Y, Bushweller JH.

Nat Struct Mol Biol. 2018 Feb;25(2):163-169. doi: 10.1038/s41594-018-0022-z. Epub 2018 Jan 29.

5.

A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cells.

Oo ZM, Illendula A, Grembecka J, Schmidt C, Zhou Y, Esain V, Kwan W, Frost I, North TE, Rajewski RA, Speck NA, Bushweller JH.

Leuk Lymphoma. 2018 Sep;59(9):2188-2200. doi: 10.1080/10428194.2017.1410882. Epub 2017 Dec 18.

6.

Corrigendum to: "Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers" [EBioMedicine 8 (2016) 117-131].

Illendula A, Gilmour J, Grembecka J, Tirumala VSS, Boulton A, Kuntimaddi A, Schmidt C, Wang L, Pulikkan JA, Zong H, Parlak M, Kuscu C, Pickin A, Zhou Y, Gao Y, Mishra L, Adli M, Castilla LH, Rajewski RA, Janes KA, Guzman ML, Bonifer C, Bushweller JH.

EBioMedicine. 2017 Nov;25:188. doi: 10.1016/j.ebiom.2017.10.029. Epub 2017 Oct 31. No abstract available.

7.

RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia.

Choi A, Illendula A, Pulikkan JA, Roderick JE, Tesell J, Yu J, Hermance N, Zhu LJ, Castilla LH, Bushweller JH, Kelliher MA.

Blood. 2017 Oct 12;130(15):1722-1733. doi: 10.1182/blood-2017-03-775536. Epub 2017 Aug 8.

PMID:
28790107
8.

Bacillus anthracis Peptidoglycan Integrity Is Disrupted by the Chemokine CXCL10 through the FtsE/X Complex.

Margulieux KR, Liebov BK, Tirumala VSKKS, Singh A, Bushweller JH, Nakamoto RK, Hughes MA.

Front Microbiol. 2017 Apr 27;8:740. doi: 10.3389/fmicb.2017.00740. eCollection 2017.

9.

Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.

Castilla LH, Bushweller JH.

Adv Exp Med Biol. 2017;962:229-244. doi: 10.1007/978-981-10-3233-2_15. Review.

PMID:
28299661
10.

Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers.

Illendula A, Gilmour J, Grembecka J, Tirumala VSS, Boulton A, Kuntimaddi A, Schmidt C, Wang L, Pulikkan JA, Zong H, Parlak M, Kuscu C, Pickin A, Zhou Y, Gao Y, Mishra L, Adli M, Castilla LH, Rajewski RA, Janes KA, Guzman ML, Bonifer C, Bushweller JH.

EBioMedicine. 2016 Jun;8:117-131. doi: 10.1016/j.ebiom.2016.04.032. Epub 2016 Apr 29. Erratum in: EBioMedicine. 2017 Nov;25:188.

11.

MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation.

Huang Y, Thoms JA, Tursky ML, Knezevic K, Beck D, Chandrakanthan V, Suryani S, Olivier J, Boulton A, Glaros EN, Thomas SR, Lock RB, MacKenzie KL, Bushweller JH, Wong JW, Pimanda JE.

Leukemia. 2016 Jul;30(7):1552-61. doi: 10.1038/leu.2016.55. Epub 2016 Mar 8.

12.

Tom1 Modulates Binding of Tollip to Phosphatidylinositol 3-Phosphate via a Coupled Folding and Binding Mechanism.

Xiao S, Brannon MK, Zhao X, Fread KI, Ellena JF, Bushweller JH, Finkielstein CV, Armstrong GS, Capelluto DGS.

Structure. 2015 Oct 6;23(10):1910-1920. doi: 10.1016/j.str.2015.07.017. Epub 2015 Aug 27.

13.

Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.

Kuntimaddi A, Achille NJ, Thorpe J, Lokken AA, Singh R, Hemenway CS, Adli M, Zeleznik-Le NJ, Bushweller JH.

Cell Rep. 2015 May 5;11(5):808-20. doi: 10.1016/j.celrep.2015.04.004. Epub 2015 Apr 23.

14.

Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.

Illendula A, Pulikkan JA, Zong H, Grembecka J, Xue L, Sen S, Zhou Y, Boulton A, Kuntimaddi A, Gao Y, Rajewski RA, Guzman ML, Castilla LH, Bushweller JH.

Science. 2015 Feb 13;347(6223):779-84. doi: 10.1126/science.aaa0314.

15.

Importance of a specific amino acid pairing for murine MLL leukemias driven by MLLT1/3 or AFF1/4.

Lokken AA, Achille NJ, Chang MJ, Lin JJ, Kuntimaddi A, Leach BI, Malik B, Nesbit JB, Zhang S, Bushweller JH, Zeleznik-Le NJ, Hemenway CS.

Leuk Res. 2014 Nov;38(11):1309-15. doi: 10.1016/j.leukres.2014.08.010. Epub 2014 Aug 24.

16.

Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.

Risner LE, Kuntimaddi A, Lokken AA, Achille NJ, Birch NW, Schoenfelt K, Bushweller JH, Zeleznik-Le NJ.

J Biol Chem. 2013 Oct 11;288(41):29901-10. doi: 10.1074/jbc.M113.474858. Epub 2013 Aug 29.

17.

Structural and dynamic studies of the transcription factor ERG reveal DNA binding is allosterically autoinhibited.

Regan MC, Horanyi PS, Pryor EE Jr, Sarver JL, Cafiso DS, Bushweller JH.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13374-9. doi: 10.1073/pnas.1301726110. Epub 2013 Jul 29.

18.

Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding.

Leach BI, Kuntimaddi A, Schmidt CR, Cierpicki T, Johnson SA, Bushweller JH.

Structure. 2013 Jan 8;21(1):176-183. doi: 10.1016/j.str.2012.11.011. Epub 2012 Dec 20.

19.

Optimal mutation sites for PRE data collection and membrane protein structure prediction.

Chen H, Ji F, Olman V, Mobley CK, Liu Y, Zhou Y, Bushweller JH, Prestegard JH, Xu Y.

Structure. 2011 Apr 13;19(4):484-95. doi: 10.1016/j.str.2011.02.002.

20.

Application of fragment-based drug discovery to membrane proteins: identification of ligands of the integral membrane enzyme DsbB.

Früh V, Zhou Y, Chen D, Loch C, Ab E, Grinkova YN, Verheij H, Sligar SG, Bushweller JH, Siegal G.

Chem Biol. 2010 Aug 27;17(8):881-91. doi: 10.1016/j.chembiol.2010.06.011.

Supplemental Content

Loading ...
Support Center